Controversies Revealed in a Multidisciplinary International Survey of Physicians. (2020)
https://pubmed.ncbi.nlm.nih.gov/32974863/

Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial. spondyloarthritis: data from 21 clinical trials. (2020)
https://pubmed.ncbi.nlm.nih.gov/32449924/

Non-radiographic axial spondyloarthritis. (2020)
https://pubmed.ncbi.nlm.nih.gov/32996809/

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). (2020)
https://pubmed.ncbi.nlm.nih.gov/31813637/

Treatment patterns and health care resource utilization among Japanese patients with ankylosing spondylitis: A hospital claims database analysis (2020)
https://pubmed.ncbi.nlm.nih.gov/32476522/

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial (2020)
https://pubmed.ncbi.nlm.nih.gov/31813637/

Clinical Characteristics of Patients with Spondyloarthritis in Japan in Comparison with Other Regions of the World (2019)
https://pubmed.ncbi.nlm.nih.gov/30770497/

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial (2018)
https://pubmed.ncbi.nlm.nih.gov/30360964/